First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.

Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, Lopez-Yurda M, Swijnenburg RJ, Punt CJA, Dutch Colorectal Cancer Study Group

Open source

DOI
10.1016/s1470-2045(23)00219-x
Published
2023 Jul
Container
The Lancet. Oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-23-00219-x,
  title = {First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.},
  author = {Bond MJG and Bolhuis K and Loosveld OJL and de Groot JWB and Droogendijk H and Helgason HH and Hendriks MP and Klaase JM and Kazemier G and Liem MSL and Rijken AM and Verhoef C and de Wilt JHW and de Jong KP and Gerhards MF and van Amerongen MJ and Engelbrecht MRW and van Lienden KP and Molenaar IQ and de Valk B and Haberkorn BCM and Kerver ED and Erdkamp F and van Alphen RJ and Mathijssen-van Stein D and Komurcu A and Lopez-Yurda M and Swijnenburg RJ and Punt CJA and Dutch Colorectal Cancer Study Group},
  year = {2023},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(23)00219-x},
  url = {https://doi.org/10.1016/s1470-2045(23)00219-x}
}

RIS

TY  - JOUR
TI  - First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
AU  - Bond MJG
AU  - Bolhuis K
AU  - Loosveld OJL
AU  - de Groot JWB
AU  - Droogendijk H
AU  - Helgason HH
AU  - Hendriks MP
AU  - Klaase JM
AU  - Kazemier G
AU  - Liem MSL
AU  - Rijken AM
AU  - Verhoef C
AU  - de Wilt JHW
AU  - de Jong KP
AU  - Gerhards MF
AU  - van Amerongen MJ
AU  - Engelbrecht MRW
AU  - van Lienden KP
AU  - Molenaar IQ
AU  - de Valk B
AU  - Haberkorn BCM
AU  - Kerver ED
AU  - Erdkamp F
AU  - van Alphen RJ
AU  - Mathijssen-van Stein D
AU  - Komurcu A
AU  - Lopez-Yurda M
AU  - Swijnenburg RJ
AU  - Punt CJA
AU  - Dutch Colorectal Cancer Study Group
PY  - 2023
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(23)00219-x
UR  - https://doi.org/10.1016/s1470-2045(23)00219-x
ER  - 

APA

MJG, B., K, B., OJL, L., JWB, D. G., H, D., HH, H., MP, H., JM, K., G, K., MSL, L., AM, R., C, V., JHW, D. W., KP, D. J., MF, G., MJ, V. A., MRW, E., KP, V. L., IQ, M., B, D. V., BCM, H., ED, K., F, E., RJ, V. A., D, M. S., A, K., M, L., RJ, S., CJA, P., & Group, D. C. C. S. (2023). First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(23)00219-x

Source records